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Introduction
• Breast cancer is prevalent in USA and
about 13% of females develop breast
cancer.1
• Radiation to breast or chest wall
follows surgery to minimize risk of
recurrence.2
• Photon radiation is used to sterilize
tissues, but side effects could develop.
• Mepilex has been shown to help
patients with skin toxicity.

Figure 1: Radiation treatment plan image

Results

Conclusion

21 of the 58 female patients were prescribed Mepilex.
Median Age (years): 65 (Range: 40 – 86)
3
Median BMI (kg/m ): 33.03 (Range: 21.18 - 46.31)
Only one patient went through mastectomy.
11 patients (52.3%) had the tumor on the left breast;
10 patients (47.7%) had right side of breast tumor.
• More than half had tumors in the upper outer area.
2
• The median breast volume is 1171.014 mm .

Patients who are older than 65 years and with a
relatively high BMI should be monitored closely and the
prescription of Mepilex could be considered earlier in
the treatment in order to reduce the skin toxicities.
Future breast cancer patients with similar
characteristics may benefit from more aggressive skin
care.
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Objectives
To assess the characteristics of patients and
understand what kind of patients will be likely to
develop skin toxicity and require Mepilex
prescription.
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• Filter the patients who are prescribed Mepilex.
• Analyze and identify the factors that impacts skin toxicities.
• Summarize the result and get conclusions.
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Figure 2: Tumor location

• Most patients (80.9%) do not have family history of
breast cancer.
• Median lymph nodes sampled = 3 (Range: 0 – 18).
Tumor Type

• Newly diagnosed breast cancer patients who received
breast radiation in 2020.
• Carefully review 58 patients’ medical records by EPIC.
• Gather tumor information from their pathology records.
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Future Directions and Recommendations

• Educate females about breast cancer and allow
them to be aware of the potential disease.
• Emphasize breast cancer screening.
• Propagate the idea of healthy diets and
maintain healthy weight to reduce the chance
of breast cancer.
• Females over 65 years old and with BMI over 32
may consider prophylactic skin care during
radiotherapy.
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Figure 3: Tumor types and percentage

• The majority of Mepilex prescription patients are either
in pT1c or pT2 stage.
• More than half of patients had radiation with mixing
beam energy to cover both the breast and the tumor site
(6mV– 15mV).
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